NOVO NORDISK
Mon, 04 Jan 2021 09:14:00 -0500
Mon, 04 Jan 2021 09:14:00 -0500
- COVID-19 Patient Assistance Program: Eligible patients can continue to enroll in our Diabetes Patient Assistance Program and receive a free 90-day supply of insulin until June 30, 2021
PLAINSBORO, N.J., Jan. 4, 2021 /PRNewswire/ -- Today, Novo Nordisk announced the extension of its COVID-19 Patient Assistance Program until June 30, 2021, for those who have lost health insurance coverage because of a change in job status due to the pandemic.
The company also would like to remind people who are currently using the My$99Insulin program that they must reregister to determine if they are eligible for the cash card program.
For people looking to find out what option makes the most sense for their particular situation, information and eligibility criteria about these and other offerings are available online at NovoCare.com or by calling 1.844.NOVO4ME (1.844.668.6463).
"Last January, we created new programs to meet the varying needs of patients whether they have insurance or don't and made them available on Novocare.com. Then, the pandemic hit and patients faced new challenges - millions of people lost their jobs and very likely their health coverage so we knew we needed to do more specific to the pandemic," said Doug Langa, Executive Vice President, North America Operations and President of Novo Nordisk Inc. "The need is still present - our nation is not back to normal and our economic and public health reality is still challenging. So, we're continuing our COVID -19 assistance program and encouraging anyone facing affordability challenges to visit our one-stop support resource to find the option most suitable to them."
Important updates in Novo Nordisk's affordability programs
Novo Nordisk offers a number of other affordability programs, including:
To learn more about these offerings and view full eligibility requirements, please visit NovoCare.com.
Additionally, we'll continue working towards longer-term reform that makes it easier for people who need our medicines to get them. For instance, we advocate that payers adopt a 2019 IRS rule classifying insulin as preventive care, which could help a significant number of people overcome affordability barriers.
About NovoCare.com
NovoCare.com is Novo Nordisk's go-to
resource for all US patient affordability and access support programs.
Available 24 hours a day, NovoCare.com provides all necessary
information, including eligibility details, affordability options,
assistance programs for those in need of insulin. Help is also
available at 1.844.NOVO4ME (668.6463).
About Novo Nordisk Inc. (NNI)
NNI is a US affiliate of
Novo Nordisk. The company is based in Plainsboro, NJ and is
responsible for commercialization of Novo Nordisk brands in the US and
management of clinical trials in the US. For more information, visit
novonordisk.us,
Facebook,
Instagram and
Twitter.
About Novo Nordisk Pharma, Inc. (NNPI)
Novo Nordisk
Pharma, Inc. (NNPI) is a newly established Novo Nordisk A/S US company
that is also based in Plainsboro, NJ. The company was formed in March
2019 to bring unbranded biologics of Novo Nordisk insulin products at
a reduced list price for people facing affordability challenges.
SOURCE Novo Nordisk